Skip to main content
SRTS logo

Sensus Healthcare, Inc. (SRTS) Stock: Price, Forecast & Analyst Target

Sensus Healthcare, Inc. (SRTS) — MoonshotScore 31/100 (Weak band), calculated Nov 18, 2026. Price $2.36 (+2.61%), as of the Nov 19, 2026 trading session; market cap $38.9M.

Educational signal · not a buy or sell recommendation · How to read this

$2.36 +$0.06 (+2.61%) Market Cap $38.9M

Sensus Healthcare, Inc. · SRTS · NASDAQ

Sensus Healthcare, Inc. (SRTS) is a medical device company specializing in superficial radiation therapy devices for treating non-melanoma skin cancers.

Price as of Nov 19, 2026

Key Statistics

31 of 100

MoonshotScore v2 · Sensus Healthcare (SRTS)

Weak
Business Quality Thin (21)
Financial Safety Sound (60)
Valuation Full (59)
Growth Durability Shrinking (3)
Momentum Slipping (38)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Bottom-tier quality, stalling growth and a full valuation. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Sound; Valuation: Full; Growth Durability: Shrinking; Momentum: Slipping.

  • quarterly revenue $6M (Q3 FY2026, quarter ended Sep 30, 2026)
  • EPS beat 1 of the last 8 reports
  • Altman Z 4.43 · Piotroski F 2

Holding back: weak fundamentals, soft growth

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for SRTS (57 recorded, newest six shown)
RecordedScoreBand
32Weak
32Weak
35Weak
35Weak
31Weak
31Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$2.36
Change on the day+2.61%
52-week range$2.31 – $5.49
Market capitalisation$38.9M—
Shares traded on the day170.3K

Price & events

Other perspectives

Council score for Sensus Healthcare (SRTS): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Weak
Financial Safety Moderate
Valuation Neutral
Growth Durability Negative
Momentum Weak

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Nov 11, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Negative
Margin of Safety Undervalued
Profit Margin Weak
Revenue Growth Negative
Debt/Equity Strong
ROE Negative
Gross Margin Neutral

Read on: Oct 8, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Oct 8, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Sensus Healthcare (SRTS), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Sensus Healthcare, Inc. (SRTS) is listed on NASDAQ. It employs 60 people and is led by Joseph C. Sardano. In Q3 FY2026 it reported revenue of $6M and net income of -$1M. The market values it at $38.9M.

2 · Latest results

What do the latest results show for Sensus Healthcare (SRTS)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of $6M. Against analyst estimates the company has EPS beat 1 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026$6M-$1M-$0.09 (diluted)
Q2 FY2026$2M-$9M-$0.53 (diluted)
Q1 FY2026$3M-$3M-$0.16 (diluted)
Q4 FY2025$5M-$3M-$0.19 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Sensus Healthcare (SRTS)?

Short answer · as of

What is holding it back is weak fundamentals, soft growth. The distress and quality screens read Altman Z 4.43 · Piotroski F 2. Trailing ratios: ROE -38.7% · ROA -39.5% · current ratio 6.77 · earnings yield -41.9% · free-cash-flow yield -30.1%.

Data-derived red flags

  • Negative return on equity (-38.7%) — the business is not currently generating profit on shareholder capital.
  • Inconsistent delivery — missed Wall Street EPS estimates in 7 of the last 8 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Sensus Healthcare (SRTS)?

Short answer · as of

Current published price targets run low $4.00 · high $5.50 · consensus $4.75 · median $4.75 against a quoted price of $2.36 (as of Nov 19, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Sensus Healthcare compare with its peers?

Short answer

Sensus Healthcare's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Intuitive Surgical, Inc. (ISRG) Named competitor$420.95 Nov 18, 2026$146B94 5-pillar Nov 18, 2026
Electromed, Inc. (ELMD) Same industry, near in market value$23.40 Nov 18, 2026$191M87 5-pillar Nov 18, 2026
Medtronic plc (MDT) Named competitor$100.72 Nov 18, 2026$129B81 5-pillar Nov 18, 2026
HCA Healthcare, Inc. (HCA) Named competitor$476.35 Nov 18, 2026$99.5B77 5-pillar Nov 18, 2026
Anika Therapeutics, Inc. (ANIK) Same industry, near in market value$13.62 Nov 18, 2026$182M71 5-pillar Nov 18, 2026
LENSAR, Inc. (LNSR) Same industry, near in market value$4.85 Nov 18, 2026$59.6M44 5-pillar Nov 18, 2026
Solana Company (HSDT) Same industry, near in market value$1.63 Nov 18, 2026$103M43 5-pillar Nov 18, 2026
Owlet, Inc. (OWLT) Same industry, near in market value$3.67 Nov 18, 2026$110M41 5-pillar Nov 18, 2026
Hyperion DeFi, Inc. (HYPD) Same industry, near in market value$2.38 Nov 18, 2026$36.2M39 5-pillar Nov 18, 2026
Inogen, Inc. (INGN) Same industry, near in market value$5.57 Nov 18, 2026$145M37 5-pillar Nov 18, 2026
Orthofix Medical Inc. (OFIX) Same industry, near in market value$6.61 Nov 18, 2026$269M36 5-pillar Nov 18, 2026
Apyx Medical Corporation (APYX) Same industry, near in market value$2.49 Nov 18, 2026$105M33 5-pillar Nov 18, 2026
Sensus Healthcare (SRTS) — this page$2.36$38.9M31

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$4.00 – $5.50
Consensus target
$4.75
Median target
$4.75

Consensus record · Captured .

Measured against a quoted price of $2.36 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Aug 31, 2026

Transactions
8
Identified insiders
2
Purchases
8
Sales
0
Other transactions
0

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held SRTS in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported SRTS in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Sensus Healthcare (SRTS)?

Read these with our analysis →

Common Questions About SRTS

These answers are editorial: 1 of these 9 answers is drawn from the SRTS research dossier (written May 9, 2026 by gpt-4o-mini); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for SRTS?

SRTS carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is SRTS a good stock to buy?

Stock Expert AI does not rate SRTS buy, sell or hold. Sensus Healthcare, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the SRTS stock price today?

The last price recorded for Sensus Healthcare, Inc. (SRTS), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the SRTS price target?

The analyst consensus price target for Sensus Healthcare, Inc. (SRTS), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What are the main risks for SRTS?

Sensus Healthcare, Inc. faces several risks, including intense competition from larger medical device companies, which could impact its market share. Regulatory challenges in obtaining approvals for new products may also delay growth.

What are the key factors to evaluate for SRTS?

Sensus Healthcare, Inc. (SRTS) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. No dividend yield, indicating a focus on reinvestment for growth. Not financial advice.

How frequently does SRTS data refresh on this page?

SRTS's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven SRTS's recent stock price performance?

Sensus Healthcare, Inc. (SRTS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative technology in superficial radiation therapy. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider SRTS overvalued or undervalued right now?

Sensus Healthcare, Inc. (SRTS) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 20 figures on this page — 12 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.